%0 Journal Article
%A Oster, Christoph
%A Reineck, Pia
%A Schmidt, Teresa
%A Grieger, Jana
%A Sharma, Sandeep
%A Feldheim, Jonas
%A Kizina, Kathrin
%A Cappello, Giorgio
%A Jekel, Leon
%A Pabst, Kim M
%A Ahmadipour, Yahya
%A Karadachi, Hanah
%A Rauschenbach, Laurel
%A Lazaridis, Lazaros
%A Guberina, Nika
%A Pöttgen, Christoph
%A Blau, Tobias
%A Keyvani, Kathy
%A Scheffler, Björn
%A Herrmann, Ken
%A Kleinschnitz, Christoph
%A Sure, Ulrich
%A Stuschke, Martin
%A Glas, Martin
%A Kebir, Sied
%T Distribution and prognostic significance of myelotoxicity in newly diagnosed glioblastoma in a real-life cohort: Time to treat more aggressively?
%J Neuro-oncology advances
%V 7
%N 1
%@ 2632-2498
%C Oxford
%I Oxford University Press
%M DKFZ-2026-00051
%P vdaf218
%D 2025
%Z Published:05 December 2025
%X Glioblastoma represents one of the most aggressive and fatal primary brain tumors in adults. Chemotherapeutic agents, while integral to management, frequently induce varying levels of myelotoxicity. The aim is to investigate the clinical impact of myelotoxicity in patients treated with the CeTeG versus the Stupp regimen which has not yet been systematically investigated under real-world conditions.This retrospective study included patients with newly diagnosed glioblastoma who underwent radiochemotherapy. Peripheral blood counts were systematically assessed throughout first-line therapy, starting at the initiation of radiation and continuing until either first disease progression or death, whichever occurred earlier.Among 161 identified patients, 133 (83
%K Pneumocysitis jirovecii prophylaxis (Other)
%K gender-specific medicine (Other)
%K glioblastoma (Other)
%K myelotoxicity (Other)
%K survival (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:41497453
%2 pmc:PMC12768505
%R 10.1093/noajnl/vdaf218
%U https://inrepo02.dkfz.de/record/307554